Clinical Trials Logo

Clinical Trial Summary

Randomized, double-masked, placebo-controlled, multiple center, parallel-group Phase 1 study to evaluate the safety and tolerability of 3 doses of preservative-free PHMB ophthalmic solution compared to placebo in healthy subjects


Clinical Trial Description

The primary objective of the study is to establish the ocular safety and tolerability, and systemic safety of 3 different concentrations of preservative-free PHMB in healthy subjects. Safety and tolerability will be compared to those of a placebo.The PHMB bioavailability in plasma will also be assessed ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02506257
Study type Interventional
Source SIFI SpA
Contact
Status Active, not recruiting
Phase Phase 1
Start date November 2015
Completion date April 2016

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06332703 - Acanthamoeba and Artificial Intelligence
Enrolling by invitation NCT03461978 - Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures N/A
Recruiting NCT02763605 - Retrospective Study of Acanthamoebic Keratitis During the Past 10 Years N/A
Active, not recruiting NCT03484507 - Parasitic Ulcer Treatment Trial Pilot Phase 2
Active, not recruiting NCT05110001 - Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction Phase 3
Completed NCT03274895 - Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis Phase 3
Not yet recruiting NCT06213649 - Parasitic Ulcer Treatment Trial Phase 3